Shanghai Medicilon Inc.

  On January 8, Dr. Xiaobao Yang, Chairman and CEO of Gluetacs Therapeutics (Gluetacs) awarded Shanghai Medicilon Inc. (Medicilon) the "2023 Best Partner Award”.  Dr. Jinna Cai, Chief Commercial Officer of Medicilon, and Bolin Zhang, Director of CMC of Key Account Development Department, attended the award ceremony. Medicilon and Gluetacs: Going in both directions, achieving each other’s achievements Dr. Xiaobao Yang, Chairman and CEO of Gluetacs, affirmed the efficient service capabilities of Medicilon’s one-stop biopharmaceutical preclinical R&D service platform at the award ceremony, “In the past two years, Gluetacs’  GT919  and GT929 have been clinically approved in China and the United States, which is inseparable from Medicilon’s strong support.  Even for difficult trials, the Medicilon team was able to deliver beyond expectations, which makes us feel reassured and confident in our future collaboration.” Dr. Jinna Cai, Chief Commercial Officer of Medic...

ADC, PROTAC, CAR-T, mRNA… Subversive innovative technologies time after time have brought hope to human beings to overcome more diseases, and made the innovative power of scientists the strongest engine to promote the biopharmaceutical industry.  However, every scientific and technological achievement is like a seed, which needs a suitable environment to germinate and be transformed and landed. According to the data of the "2021 Chinese University Science and Technology Innovation Index Evaluation Report" and "2020 American University Patent Output Ranking" researched by the XBrain, the conversion rate of scientific research achievements in Chinese universities is about 3.5%, while the conversion rate of scientific research achievements in American universities reached about 25%.  A large number of articles, achievements, and patents are hidden in the dark, and the transformation of scientific and technological achievements is still a major obstacle to the developme...

  Recently, Gluetacs Therapeutics (Gluetacs)'s first class 1 new drug, GT919 Capsules, a molecular glue degradation agent pipeline, was approved by the US Food and Drug Administration (FDA) to enter clinical trials.  It is for the treatment of malignant hematological tumors. The pipeline was previously approved by the National Medical Products Administration (NMPA) for clinical trials on December 20, 2022, and is currently undergoing Phase I clinical trials in China.  This is the first product pipeline of Gluetacs that has been approved for clinical trials in both China and the United States, and it is another milestone in the globalization process of Gluetacs.  For the research and development of GT919, Shanghai Medicilon Inc, (Medicilon) relied on its solid R&D strength to efficiently complete the drug discovery to clinical application for GT919, including drug discovery, pharmaceutical research, and preclinical research based on Medicilon's one-stop preclinica...